FDA Approves First mRNA Flu Vaccine For Older Adults

Moderna CEO Stéphane Bancel said the approval of mFLUSIVA “provides an important new option” for America’s seniors and reflects the potential of its mRNA platform. While no financial metrics were provided, the product approval is a clear positive catalyst for Moderna’s outlook and reinforces mRNA platform value.

Analysis

Moderna CEO Stéphane Bancel said the approval of mFLUSIVA “provides an important new option” for America’s seniors and reflects the potential of its mRNA platform. While no financial metrics were provided, the product approval is a clear positive catalyst for Moderna’s outlook and reinforces mRNA platform value.